Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 20 January 2020, 14:21 HKT/SGT
Share:
    

Source: Eisai
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019

TOKYO, Jan 20, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP(1), a non-profit organization, as a company that has performed particularly well in response to climate change.


The CDP is a non-profit organization based in London that requests top-ranking market capitalization companies and municipalities in principal countries to disclose information on climate change, water, and forests. After analyzing and evaluating this information, CDP discloses it to the investors, companies, and government.

Based on the Eisai Network Companies (ENW) Environmental Protection Policy, all employees recognize the importance of environmental protection and conduct business operations seeking co-existence with the global environment. In particular, with regard to climate change, Eisai has positioned it as a key issues facing society, and has set the greenhouse gas emission reduction targets based on the scientific grounds approved by Science Based Targets (SBT) initiative(2) in 2019, and has strengthened its commitment to that goal. In addition, Eisai addresses the reduction of risk and creation of opportunity by capturing the mid- and long-term effects of climate changes to its business utilizing the framework of the Task Force on Climate-related Financial Disclosure (TCFD)(3).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Under this human health care (hhc) philosophy, Eisai will strengthen its effort on climate change and contribute to ensuring the sustainability of society.

Please refer to the Environmental Report for more detailed information about our environmental activities. https://www.eisai.com/ir/library/annual/index.html

(1) Formerly known as Carbon Disclosure Project.
(2) International joint initiative led by CDP, UN Global Compact (UNGC), World Resources Institute (WRI) and World Wildlife Fund for Nature (WWF).
(3) A private sector-led task force with regard to climate-related financial information disclosure established under the Financial Stability Board (FSB) as per the request of G20 finance ministers and central bank governors.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: